Norwegian Patient Registry studies
Bakken: 74% female, ratio 3.2:1, 5,810 G93.3 cases, hospital diagnosis
Hilland: 79% female, ratio 3.7:1, 5,560 G93.3 cases, hospital diagnosis
These two studies used the same methodology, with Hilland looking at data several years later than Bakken. Both used G93.3 coding to define ME/CFS cases, and the National Patient Registry which covers all hospitalisations and outpatient visits for the entire Norwegian population. The studies focused on incidence by age and sex, but also calculated an overall sex ratio.
The studies differ in two findings. Hilland (data from 2016-18) found a higher proportion of women than Bakken (data from 2008-16) i.e 79% versus 74%, and a higher substantially higher rate of diagnosis: 36 vs 28/100k. The question is, why?
A couple of things appear likely:
1. Increased awareness of ME/CFS amongst patients and doctors
In 2011, Fluge and Mella published the stunning finding of their Rituximab pilot study. This led to even more publicity in Norway than elsewhere, which was boosted by Dr Maria Gjerpe’s MEandYOU remarkable media campaign to raise funds for further research. There was a lot of debate in Norway’s media, and even an apology from a Government minister to patients for the neglect of the illness.
Increased awareness amongst patience and doctors is likely to have led to increased referral to hospital, as Hilland et al suggest.
2. 2014 official guidelines of how to diagnose and code ME/CFS
In 2014, the National Directorate of Public Health, where Inger Bakken is a senior adviser, issued the first national guidelines for ME/CFS advising on correct diagnosis including excluding alternative explanations, and the need to code with G93.3. This is likely to have improved accuracy of diagnosis and may be behind the increase in sex ratio.